Regional rCBF before and after treatment
| rCBF (ml/min/100g) | Before Treatment | 6 Months After Treatment | P Value* |
|---|---|---|---|
| Symptomatic patients (n = 10) | |||
| Resting | 23.3 ± 5.1 | 26.8 ± 7.3 | .1849 |
| Acetazolamide | 27.1 ± 5.1 | 38.0 ± 12.4 | .0166 |
| ΔF† | 3.9 ± 2.7 | 11.2 ± 7.0 | .0367 |
| Asymptomatic patients (n = 4) | |||
| Resting | 28.8 ± 8.2 | 30.1 ± 6.4 | >.05 |
| Acetazolamide | 38.4 ± 7.6 | 47.4 ± 8.6 | .0679 |
| ΔF† | 9.7 ± 2.6 | 17.2 ± 6.9 | .0679 |
* Wilcoxon signed rank test.
† Acetazolamide rCBF − resting rCBF.